Insulet Corporation reported fourth-quarter revenue of $783.8 million, exceeding analyst expectations of $768.59 million and marking a 31.2% year-over-year increase. The tubeless insulin pump maker's shares rose 1.3% following the announcement, driven by strong performance across its Omnipod product line.

Total Omnipod revenue reached $781.8 million, up 33.5% YoY, with U.S. revenue increasing 28% to $567.8 million and international revenue surging 50.7% to $214 million. The company achieved a gross margin of 72.5%, up 40 basis points from the previous year. However, earnings per share came in at $1.44, slightly below the analyst estimate of $1.46.

For the first quarter of 2026, Insulet expects total revenue growth of 25% to 27% in constant currency, with Omnipod product revenue projected to increase 28% to 30%. The company's full-year 2026 guidance forecasts total revenue growth of 20% to 22% in constant currency, with adjusted operating margin expansion of approximately 100 basis points YoY and adjusted EPS growth exceeding 25%. Insulet also announced a $350 million increase in its share repurchase authorization, with plans to allocate approximately $300 million toward repurchases in the first quarter of 2026.